Cidofovir

Generic Name: Cidofovir

Brand Names: Vistide

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄N_₃O_₆P

CAS Number: 113852-37-2

Unique Ingredient Identifier: 768M1V522C

Background: Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis. It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued.

Indication: 用于治疗免疫功能缺陷患者不能耐受更昔洛韦和膦甲酸钠治疗或治疗无效的巨细胞病毒感染。

Associated Conditions: Cytomegalovirus Retinitis, Herpes Simplex Virus, Monkeypox, Variola Major (Smallpox)

Clinical Trials

Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis

Not Applicable

Withdrawn

Conditions: Bladder Diseases
Cystitis

Interventions: Drug: Cidofovir

First Posted Date: 2009-08-11

Last Posted Date: 2019-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00956176

Trial of Topical Cidofovir for the Prevention of Hair Growth

Phase 2

Completed

Conditions: Prevention of Hair Growth

Interventions: Drug: 1% topical cidofovir
Drug: 3% topical cidofovir
Drug: Placebo

First Posted Date: 2009-07-29

Last Posted Date: 2012-03-19

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT00948506

Locations: 🇺🇸
Hospital of the University of PA, Philadelphia, Pennsylvania, United States

Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy

Phase 1

Conditions: Cervical Cancer
Precancerous Condition

First Posted Date: 2008-12-19

Last Posted Date: 2010-01-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 24

Registration Number: NCT00811408

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

Phase 2

Completed

Conditions: Precancerous Condition
Anal Cancer

Interventions: Drug: cidofovir
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: polymerase chain reaction
Procedure: biopsy
Procedure: histopathologic examination

First Posted Date: 2007-10-30

Last Posted Date: 2015-12-21

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 33

Registration Number: NCT00550589

Locations: 🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
🇺🇸
Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States

and more 5 locations

Use of Cidofovir for Recurrent Respiratory Papillomatosis

Phase 4

Completed

Conditions: Recurrent Respiratory Papillomatosis

Interventions: Drug: Placebo
Drug: Cidofovir

First Posted Date: 2005-09-20

Last Posted Date: 2019-02-26

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 19

Registration Number: NCT00205374

Cidofovir in Renal Transplant Recipients With BKVN

Phase 1

Terminated

Conditions: BK Virus (Nephropathy)

Interventions: Drug: Cidofovir
Drug: Placebo

First Posted Date: 2005-08-30

Last Posted Date: 2013-03-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00138424

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center - Infectious Disease, Lebanon, New Hampshire, United States
🇺🇸
California Pacific Medical Center - Sutter Pacific Medical Foundation - Transplant Nephrology, San Francisco, California, United States
🇺🇸
Mayo Clinic, Rochester - Infectious Diseases, Rochester, Minnesota, United States

and more 9 locations

Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-04-21

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019240

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000799

Locations: 🇺🇸
Johns Hopkins Hosp / SOCA, Baltimore, Maryland, United States
🇺🇸
UCSD - Shiley Eye Ctr / SOCA, La Jolla, California, United States
🇺🇸
UCLA - Jules Stein Eye Institute / SOCA, Los Angeles, California, United States

and more 4 locations

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

Phase 4

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-02-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000894

Locations: 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
New York Hosp / Cornell Med Ctr, New York, New York, United States

and more 9 locations

Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)

Phase 1

Completed

Conditions: Papilloma

First Posted Date: 2001-08-31

Last Posted Date: 2010-08-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00001126

Locations: 🇺🇸
NIAID/DMID/CASG Central Unit, Birmingham, Alabama, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy